The new orally active angiotensin II (A II) type-1 receptor antagonist olmesartan medoxomil is a prodrug, which is rapidly converted in vivo to the active metabolite, olmesartan. The pharmacology, antihypertensive efficacy and safety of olmesartan medoxomil and/or the pharmacologically active metabolite, olmesartan, have been evaluated in both non-clinical and clinical models. Orally administered olmesartan medoxomil is rapidly absorbed from the gastrointestinal tract and converted during absorption to olmesartan, which is subsequently excreted without further metabolism. Peak plasma concentrations of olmesartan occur 1-3 h after administration, after which concentrations decrease with an elimination half-life of 10-15 h. The absolute bioavailability of olmesartan from olmesartan medoxomil tablets is 28.6%. In a single-dose crossover study in 16 patients with mild-to-moderate hypertension receiving a sodium-restricted diet, statistically significant lowering
Introduction
The potentially harmful pressor effect of angiotensin II (A II) has long been recognized, and A II blockade, first using angiotensin-converting enzyme (ACE) inhibitors and more recently with A II type-1 receptor (AT 1 receptor) antagonists, has been an exciting development that has completely changed the management of clinical hypertension and congestive heart failure. 1 Orally active olmesartan medoxomil is among the latest A II antagonists to be developed. Olmesartan medoxomil is a prodrug that is rapidly converted in vivo to the pharmacologically active metabolite, olmesartan. The pharmacological properties and promising efficacy and safety profiles of olmesartan medoxomil are discussed in this overview. I-labelled A II with an IC 50 of 8.0 ± 0.8 nmol/l, but does not affect binding to the bovine cerebellar membrane AT 2 receptor (IC 50 Ͼ 100 000 nmol/l). The affinity of olmesartan for the AT 1 receptor is higher than that of, for example, losartan (IC 50 92 ± 5 nmol/l). 
Pharmacokinetic parameters
The medoxomil ester of olmesartan was developed in preference to the active compound olmesartan, because the oral bioavailability of the latter is low (4.5%) and is increased (to 28.6%) 3 by esterification with the medoxomil moiety. Following oral administration of olmesartan medoxomil in humans and animals, the intact parent ester has not been observed in measurable amounts in plasma or excreta. Absorption of olmesartan in humans following oral dosing with the medoxomil ester is rapid (t max 1-3 h). Systemic availability (measured as olmesartan maximum concentration (C max ) and area under the curve (AUC) values) increases linearly, or nearly so, over the therapeutic dose range, although the increases are slightly less than dose-proportional at higher doses.
The mean plasma elimination half-life of olmesartan in humans ranges from 10 to 15 h after multiple oral doses. The major route of excretion of olmesartan is in the faeces. Urinary excretion accounts for 10-16% of the administered dose. However, only a fraction (26%) of the administered dose is available systemically and, of this, up to half is excreted in the urine and the remainder in the faeces with unabsorbed drug.
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Effect of potential risk-group status on pharmacokinetics
In four studies, the influence of hypertensive patients' risk status on pharmacokinetic parameters of olmesartan medoxomil was investigated. 4 The parameters in elderly, very elderly, renally impaired and hepatically impaired patients were compared with appropriate controls as follows:
• elderly patients (65-75 years) (n = 12) vs 12 younger patients (18-45 years); 80 mg/day for 10 days; • very elderly patients (у75 years) (n = 17) vs 16 younger patients (18-45 years); 10 mg/day for 14 days; • renally impaired patients (65-75 years) (eight mild, nine moderate, nine severe) vs eight healthy controls (41-47 years); 10 mg/day for 7 days; • (in the USA only) hepatically impaired patients (26-72 years) (four mild, eight moderate) vs 12 healthy controls (45-59 years); single oral dose of 10 mg olmesartan medoxomil and after 10 days washout 8 mg olmesartan medoxomil intravenously over 5 min. 4 As shown in Table 2 , C max and AUC at steady state were greater than controls for all patient groups except for those with mild hepatic impairment. In patients with severe renal impairment, in whom exposure is increased 2.79-fold compared with healthy subjects, caution is required when starting therapy, and the daily dose of olmesartan medoxomil should not exceed 20 mg. The results of this study suggest that dosage adjustments in the populations tested may not be needed except for patients with severe renal impairment. The increased plasma concentrations of olmesartan in elderly and very elderly patients, and in patients with mild and moderate renal and hepatic impairment, were still several-fold lower than those observed in other studies, where concentrations achieved after 80 mg olmesartan medoxomil daily were well tolerated. 
Drug interactions
The potential for drug interactions with olmesartan medoxomil has been evaluated using in vitro and in vivo studies. This drug has no or minimal inhibitory effects on human cytochrome P-450 activities at therapeutic concentrations in vitro. A recent review concludes that interactions between olmesartan medoxomil and co-administered warfarin, digoxin or the antacid aluminium magnesium hydroxide are not clinically significant, and that olmesartan medoxomil appears to have a low interactive potential. 
Clinical antihypertensive efficacy of olmesartan medoxomil
The blood pressure (BP)-lowering effects of olmesartan medoxomil have been confirmed in a model pharmacodynamic study in hypertensive patients in whom the renin-angiotensin system was stimulated by a low-sodium diet for 3 days and a single 40 mg dose of oral furosemide. 5 In this pharmacodynamic model, two groups of eight patients each received three single olmesartan medoxomil doses and placebo using a crossover method. Blood pressures were recorded by ambulatory monitoring. The study showed that doses of olmesartan medoxomil in the range 10-80 mg are more effective than placebo in lowering BP (Table 3) . 6 A clinical programme comprising 14 phase II and phase III studies confirmed the BP-lowering effect of olmesartan medoxomil. In these studies over 5000 patients were randomized, and more than 3500 were treated with olmesartan medoxomil. About half of these patients received long-term olmesartan medoxomil, including over 800 for at least 6 months, over 500 for at least 1 year, and over 360 patients who took olmesartan medoxomil for 2 years (including more than 60 patients aged у75 years). Table 4 shows the mean efficacy data at week 12, from a pivotal phase II dose-ranging study, 6 and at Journal of Human Hypertension week 8 from another study. 8 In the study with 12 weeks follow-up, all doses of olmesartan medoxomil from 10 mg/day to 80 mg/day were superior to placebo in respect of the primary efficacy measure, mean decrease in sitting diastolic BP (DBP) between baseline and final visit, and in response rates. In the study with 8 weeks' follow-up, doses of 2.5-40 mg caused significant mean decreases in sitting diastolic and systolic BP (SBP).
As indicated in Table 5 , the 20 mg and 40 mg doses of olmesartan medoxomil were significantly superior to the 5 mg dose at all time points, and the 40 mg dose was superior to the 10 mg dose at weeks 4, 8 and 12. In the integrated efficacy analysis, as in individual studies, the 40 mg dose was numerically superior to the 20 mg dose in reducing SBP. In the key dose-ranging study, 6 the 40 mg dose was also numerically superior to the 20 mg dose in reducing DBP and in responder rate. A dose of 40 mg may be beneficial in patients who do not respond adequately to a 20 mg dose.
Of special interest is an 8-week study that was conducted to evaluate the efficacy of olmesartan medoxomil dosing regimens of 5, 20 and 80 mg once or twice daily in 289 patients (DBP 100-115 mm Hg). In addition to conventional (cuff) BP measurement, 24-h ambulatory BP monitoring was used. Both methods showed that there were no significant differences between once-and twice-daily dosing regimens (Figure 1 ). Table 6 shows the incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs) overall, and those judged to be even remotely related to treatment, in patients receiving olmesartan medoxomil in the placebo-controlled studies. Overall and treatment-related incidences of AEs and SAEs are similar for the olmesartan medoxomil and placebo groups of patients.
Clinical safety and tolerability
There were no dose relationships for incidences of overall or related AEs. 7, 9 The most frequently reported AE was headache ( Table 7) . The most notable difference between olmesartan medoxomil and placebo was in dizziness (2.3% vs 0.4% of patients), which may be related to the pharmacodynamic effect of the active drug. 9 There were no clinically significant differences in the effects of olmesartan medoxomil and placebo on liver enzymes (alanine and aspartate aminotransferases, alkaline phosphatase and ␥-glutamyltransferase) or total bilirubin, and there was no evidence of any AEs on liver function. There were no clinically significant changes in other laboratory test parameters.
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